Peptable

Acetyl tetrapeptide-5

is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation

Peptide

Alanine

Ala / A · hydrophobic residue · neutral charge

Amino acid

AOD-9604

is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials

Peptide

Arginine

Arg / R · basic residue · positive charge

Amino acid

Argireline

is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner

Peptide

Asparagine

Asn / N · polar residue · neutral charge

Amino acid

Aspartic acid

Asp / D · acidic residue · negative charge

Amino acid

BPC-157

is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects

Peptide

Article index

Peptide articles

A growing collection of peptide profiles covering structure, mechanisms, research status, and the main limits of the available evidence.

Preclinical with limited human data3 references

BPC-157

Experimental peptide with predominantly preclinical tendon, muscle, and gastrointestinal research.

# BPC‑157 vs TB‑500 for Soft‑Tissue Repair: What Animal Studies Actually Show8 references

BPC-157 vs TB-500 for Soft-Tissue Repair

Comparative review of mechanisms and preclinical findings for two widely discussed soft-tissue repair peptides.

# CJC‑1295 vs Ipamorelin: Growth Hormone Secretagogues Compared7 references

CJC-1295 vs Ipamorelin

Mechanism-focused comparison of two growth hormone secretagogues with limited long-term clinical outcome data.

In healthy adults, phase 1 data showed dose‑dependent 2‑ to 10‑fold increases in mean GH and 13 references

CJC-1295

Long-acting GHRH analogue with early-phase human endocrine data and limited long-term outcomes.

Placebo‑controlled clinical studies in middle‑aged women have reported improved skin laxity, clarity, firmness, and wrinkle appearance with topical GHK‑Cu compared to vitamin C or retinoic acid creams3 references

GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper)

Topical copper peptide complex studied for collagen support, skin quality, and wound-repair biology.

Multiple phase 3 programs, including PIONEER (oral semaglutide) and STEP (injectable semaglutide for obesity), have shown significant reductions in HbA1c and body weight versus placebo in diverse populations3 references

GLP-1 Receptor Agonists (Semaglutide Focus)

Evidence-focused overview of GLP-1 receptor agonists in diabetes and chronic weight management.

Early clinical3 references

Kisspeptin

Reproductive neuroendocrine peptide system with strong human physiology relevance and early clinical translation.

For CJC-1295, the main published human study is an early randomized, placebo-controlled dose-escalation program lasting 28 and 49 days in healthy adults8 references

Long-term Risks of CJC-1295 and Ipamorelin

Long-term risk cannot be quantified from current evidence because human data are short-term and centered on hormone responses, not multi-year outcomes.

A 2024 clinical trial with 10 g/day collagen peptides for 8 weeks reported significant improvements in skin firmness and elasticity compared with baseline and placebo7 references

Oral Collagen Peptides for Skin

Short-term randomized studies suggest modest improvements in elasticity, hydration, and visible photoaging markers.

Clinically studied3 references

Semaglutide

Clinically studied GLP-1 receptor agonist with robust obesity and cardiometabolic trial evidence.

Preclinical with limited human data3 references

Thymosin Beta-4

Endogenous actin-binding peptide with broad repair-oriented preclinical literature and limited human data.